Holen Sie sich die Stockscreener-App
124.91
1.88%
-2.3191
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$127.23
Offen:
$126.69
24-Stunden-Volumen:
3.14M
Relative Volume:
0.49
Marktkapitalisierung:
$155.10B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.00
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+2.77%
1M Leistung:
-3.66%
6M Leistung:
+2.87%
1J Leistung:
+15.59%
1-Tages-Spanne:
$124.71
$128.20
1-Wochen-Bereich:
$121.79
$128.20
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, NVS, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
124.92 | 154.33B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,113.99 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.43 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
221.34 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
151.16 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
114.91 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences (GILD) Seeks FDA Approval for Weekly HIV Prevention Pill - GuruFocus
GILD Receives FDA Acceptance for Yeztugo as HIV Preventative - GuruFocus
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
FDA accepts Gilead application for once-weekly oral HIV prevention pill - Investing.com Canada
Director sale notice: GILD (NASDAQ: GILD) files Form 144 for 9,000 shares - Stock Titan
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention - Yahoo Finance Singapore
Morgan Stanley files Rule 144 for GILD common shares (GILD) - Stock Titan
Regulatory Milestone Boosts Gilead’s Presence in Liver Disease Care - Insider Monkey
Former Gilead COO Asks Judge to Nix `Rape’ in Woman’s Harassment Trial - MyNewsLA.com
Gilead Sciences Patent Application Challenged Over Potential Impact on ARIPO Contracting States - pan african visions
Panagora Asset Management Inc. Sells 321,348 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Public Employees Retirement Association of Colorado Has $111.55 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Resources Management Corp CT ADV Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Arax Advisory Partners Has $3.60 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Atlas Capital Advisors Inc. Takes $1.01 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
177,100 Shares in Gilead Sciences, Inc. $GILD Purchased by Adams Diversified Equity Fund Inc. - MarketBeat
Gilead Sciences (GILD) Reports Positive Phase 3 IDEAL Results for Livdelzi in PBC - Insider Monkey
Voya Global High Dividend Low Volatility Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Victory Capital Management Inc. Sells 109,808 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by State Street Corp - MarketBeat
Gilead (GILD) Supports Faster South Africa Access to Lenacapavir - Insider Monkey
Martingale Asset Management L P Acquires 21,153 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Rhenman & Partners Asset Management AB Buys 46,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Titan Investment Solutions Ltd Invests $6.20 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Trillium Asset Management LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Macquarie Group Ltd. Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Banco Santander S.A. - MarketBeat
Castleark Management LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
4,220,501 Shares in Gilead Sciences, Inc. $GILD Bought by Boston Partners - MarketBeat
Gross profit of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView
Enterprise value of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView
Net income before discontinued operations of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView
Long term debt to total assets ratio of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView
Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Dividends – BCBA:GILD.CI - TradingView
Long term debt to total equity ratio of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView
GILD Donates Antiviral Therapy to Support Ebola Response in Ugan - GuruFocus
Gilead donates remdesivir to Uganda for Ebola outbreak response - Investing.com
Gilead donates remdesivir to Uganda for Ebola outbreak response By Investing.com - Investing.com Canada
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief - Business Wire
UniSuper Management Pty Ltd Sells 124,258 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Vaughan David Investments LLC IL Invests $33.80 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Xponance LLC Has $29.15 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Sector Gamma AS - MarketBeat
Swiss National Bank Has $417.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Te Ahumairangi Investment Management Ltd Sells 8,180 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Meiji Yasuda America Inc Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nuveen LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Great Lakes Advisors LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by DJE Kapital AG - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Jun 15 '26 |
Sale |
125.40 |
3,000 |
376,200 |
171,646 |
0.07%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):